LENEXA, Kan.--(BUSINESS WIRE)--May 15, 2006--VasoGenix Pharmaceuticals Inc. (www.vasogenix.net) announced today that it has entered into an agreement with Cleveland Clinic to utilize the Clinic's expertise in clinical cardiovascular research on the application of VasoGenix's first drug, Calcitonin Gene Related Peptide ('CGRP'), for the treatment of heart failure. The Clinic will prepare a clinical protocol design for a Phase I/II trial to be conducted at the Clinic and coordinated by the Cleveland Clinic Cardiovascular Coordinating Center (C5). In addition, the Clinic will assist VasoGenix in its discussions with the FDA.
